RNA as a drug target: the next frontier for medicinal chemistry
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH
[2024]
|
| Ausgabe: | 1. Auflage |
| Schriftenreihe: | Methods and principles in medicinal chemistry
|
| Schlagworte: | |
| Online-Zugang: | http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-35100-8/ Inhaltsverzeichnis |
| Beschreibung: | xvi, 392 Seiten Illustrationen, Diagramme |
| ISBN: | 9783527351008 |
Internformat
MARC
| LEADER | 00000nam a22000008c 4500 | ||
|---|---|---|---|
| 001 | BV049840072 | ||
| 003 | DE-604 | ||
| 005 | 20240917 | ||
| 007 | t | ||
| 008 | 240828s2024 gw a||| |||| 00||| eng d | ||
| 015 | |a 23,N41 |2 dnb | ||
| 016 | 7 | |a 1305295714 |2 DE-101 | |
| 020 | |a 9783527351008 |c hardback : EUR 159.00 (DE) (freier Preis), circa EUR 142.90 (AT) (freier Preis) |9 978-3-527-35100-8 | ||
| 035 | |a (OCoLC)1452586964 | ||
| 035 | |a (DE-599)DNB1305295714 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BW | ||
| 049 | |a DE-29 | ||
| 084 | |8 1\p |a 540 |2 23sdnb | ||
| 245 | 1 | 0 | |a RNA as a drug target |b the next frontier for medicinal chemistry |c edited by John Schneekloth and Martin Pettersson |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c [2024] | |
| 264 | 4 | |c © 2024 | |
| 300 | |a xvi, 392 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a Methods and principles in medicinal chemistry | |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Zielstruktur |0 (DE-588)1028794711 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a RNS |0 (DE-588)4076759-0 |2 gnd |9 rswk-swf |
| 653 | |a Biochemie | ||
| 653 | |a Biochemistry | ||
| 653 | |a Biomolecules (DNA, RNA, Peptides, etc.) | ||
| 653 | |a Biomoleküle (DNA, RNA, Peptide) | ||
| 653 | |a Biowissenschaften | ||
| 653 | |a CH61: Wirkstoffforschung u. -entwicklung | ||
| 653 | |a CHB1: Biomoleküle (DNA, RNA, Peptide) | ||
| 653 | |a Chemie | ||
| 653 | |a Chemistry | ||
| 653 | |a Drug Discovery & Development | ||
| 653 | |a LS36: Biochemie | ||
| 653 | |a Life Sciences | ||
| 653 | |a Wirkstoffforschung u. -entwicklung | ||
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a RNS |0 (DE-588)4076759-0 |D s |
| 689 | 0 | 1 | |a Zielstruktur |0 (DE-588)1028794711 |D s |
| 689 | 0 | 2 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Schneekloth, John |0 (DE-588)1339302640 |4 edt | |
| 700 | 1 | |a Pettersson, Martin |0 (DE-588)1339302675 |4 edt | |
| 710 | 2 | |a Wiley-VCH |0 (DE-588)16179388-5 |4 pbl | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, ePDF |z 978-3-527-84043-4 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, ePub |z 978-3-527-84044-1 |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe, oBook |z 978-3-527-84045-8 |
| 856 | 4 | 2 | |m X:MVB |u http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-35100-8/ |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=035180035&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 883 | 1 | |8 1\p |a vlb |d 20231007 |q DE-101 |u https://d-nb.info/provenance/plan#vlb | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-035180035 | |
Datensatz im Suchindex
| _version_ | 1812973953176567808 |
|---|---|
| adam_text |
CONTENTS
SERIES
EDITORS
'
PREFACE
XIII
PREFACE
XV
1
INTRODUCTION
1
JOHN
SCHNEEKLOTH
JR.
AND
MARTIN
PETTERSSON
REFERENCES
4
2
RNA
STRUCTURE
PROBING,
DYNAMICS,
AND
FOLDING
7
DANNY
INCARNATO
2.1
2.1.1
2.1.2
2.2
2.2.1
2.2.1.1
2.2.2
2.2.2.1
2.2.3
2.2.3.1
2.3
2.4
2.5
INTRODUCTION
7
RELEVANCE
OF
RNA
STRUCTURE
IN
DISEASE
8
CHALLENGES
IN
STUDYING
RNA
STRUCTURES
8
EXPERIMENTALLY
GUIDED
RNA
STRUCTURE
MODELING
9
STRUCTURAL
INTERROGATION
OF
RNA
NUCLEOTIDES
VIA
CHEMICAL
PROBING
10
LIMITS
OF
RNA
CHEMICAL
PROBING
12
DIRECT
MAPPING
OF
RNA-RNA
INTERACTIONS
14
LIMITS
OF
RNA-RNA
INTERACTION
MAPPING
16
MAPPING
SPATIALLY
PROXIMAL
NUCLEOTIDES
IN
RNA
MOLECULES
17
LIMITS
OF
METHODS
FOR
SPATIAL
PROXIMITY
MAPPING
17
DEALING
WITH
RNA
STRUCTURE
HETEROGENEITY
19
QUERYING
RNA-SMALL
MOLECULE
INTERACTIONS
WITH
CHEMICAL
PROBING
22
CONCLUSIONS
AND
FUTURE
PROSPECTS
22
REFERENCES
23
3
HIGH-RESOLUTION
STRUCTURES
OF
RNA
29
LUKAS
BRAUN,
ZAHRA
ALIREZAEIZANJANI,
ROBERTA
TESCH,
AND
HAMED
KOOSHAPUR
3.1
3.2
3.3
3.4
3.5
3.6
INTRODUCTION
29
X-RAY
CRYSTALLOGRAPHY
31
NMR
SPECTROSCOPY
34
CRYO-EM
37
3D
STRUCTURE
PREDICTION
AND
INTEGRATIVE
APPROACHES
39
CONCLUSIONS
43
ACKNOWLEDGMENTS
43
CONFLICTS
OF
INTEREST
43
REFERENCES
43
VI
CONTENTS
4
SCREENING
AND
LEAD
GENERATION
TECHNIQUES
FOR
RNA
BINDERS
49
GARY
FREY,
EMILY
GARCIA
SEGA,
AND
NEIL
LAJKIEWICZ
4.1
KNOWLEDGE-BASED
VERSUS
AGNOSTIC
SCREENING
49
4.2
VIRTUAL
SCREENING
50
4.3
SCREENING
METHODS
51
4.3.1
HIGH-THROUGHPUT
SCREENING
(HTS)
51
4.3.1.1
MASS
SPECTROMETRY
51
4.3.1.2
HTS
OF
RNA
USING
DIRECT
MS
APPROACHES
52
4.3.1.3
HTS
OF
RNA
USING
INDIRECT
MS
APPROACHES
54
4.3.1.4
DNA-ENCODED
LIBRARIES
(DELS)
56
4.3.1.5
MICROARRAY
SCREENING
57
4.3.1.6
FRAGMENT-BASED
DRUG
DISCOVERY
58
4.3.1.7
PHAGE
DISPLAY
63
4.3.2
ORTHOGONAL
METHODS
63
4.3.2.1
SURFACE
PLASMON
RESONANCE
63
4.3.2.2
FLUORESCENCE-BASED
ASSAYS
66
4.3.2.3
MICROSCALE
THERMOPHORESIS
(MST)
70
4.3.2.4
ISOTHERMAL
TITRATION
CALORIMETRY
(ITC)
70
4.4
BINDING
SITE
IDENTIFICATION/TARGET
ENGAGEMENT
72
4.4.1
COVALENT
METHODS
72
4.4.2
COMPETITION
WITH
AN
ANTISENSE
OLIGONUCLEOTIDE
(ASO)
74
4.5
DEFINING
SAR
AND
FUNCTIONAL
ASSAYS
75
4.5.1
FUNCTIONAL
ASSAYS
75
4.5.2
PHENOTYPIC
SCREENS
76
4.6
IDENTIFYING
A
LEAD
SERIES
76
4.6.1
HIT
OPTIMIZATION
77
4.6.2
RISDIPLAM
HIT-TO-LEAD
78
4.6.3
BRANAPLAM
LEAD
GENERATION
79
4.6.4
ZOTATIFIN
LEAD
GENERATION
80
4.7
CONCLUDING
THOUGHTS
AND
OUTLOOK
80
ACKNOWLEDGMENTS
81
REFERENCES
81
5
CHEMICAL
MATTER
THAT
BINDS
RNA
93
EMILY
G.
SWANSON
HAY,
ZHENGGUO
CAI,
AND
AMANDA
E.
HARGROVE
5.1
INTRODUCTION
93
5.2
NATURAL
LIGANDS
94
5.2.1
AMINOGLYCOSIDES
94
5.2.2
TETRACYCLINES
95
5.2.3
MACROLIDES
96
5.2.4
NATIVE
RIBOSWITCH
LIGANDS
96
5.3
COMMERCIAL
LIGANDS
97
5.3.1
INDUSTRIAL
LIBRARIES
98
5.3.2
ACADEMIC
LIBRARIES
98
CONTENTS
VII
5.4
5.4.1
5.4.2
5.4.3
5.4.4
5.4.5
5.4.6
5.5
5.5.1
5.5.2
5.5.3
5.6
SYNTHETIC
LIGANDS
99
BENZIMIDAZOLES
AND
PURINES
100
NAPHTHALENES,
QUINOLINES,
AND
QUINAZOLINES
101
OXAZOLIDINONES
102
AMILORIDES
102
DIPHENYL
FURAN
103
MULTIVALENT
LIGANDS
103
COMPUTATIONAL
TOOLS
FOR
THE
EXPLORATION
OF
CHEMICAL
SPACE
103
SIMILARITY
SEARCHES
AND
PRINCIPAL
COMPONENT
ANALYSIS
104
ADDITIONAL
MACHINE-LEARNING
TOOLS
105
STRUCTURE-BASED
LIGAND
DESIGN
106
CASE
STUDIES
IN
EXAMINING
AND
EXPANDING
RNA-TARGETED
CHEMICAL
SPACE
106
5.6.1
5.6.2
USING
QSAR
TO
PROBE
RNA-TARGETING
SMALL-MOLECULE
PROPERTIES
107
EVALUATING
THE
CHEMICAL
SPACE
OF
NATURAL,
SYNTHETIC,
AND
COMMERCIAL
LIGANDS
108
5.7
CONCLUSIONS
AND
OUTLOOK
111
ACKNOWLEDGMENTS
111
REFERENCES
111
6
MICRORNAS
AS
TARGETS
FOR
SMALL-MOLECULE
BINDERS
119
MARIA
DUCA
6.1
6.2
6.3
6.4
6.4.1
INTRODUCTION
119
MICRORNAS
121
MICRORNAS
BIOGENESIS
122
TARGETING
MICRORNAS
WITH
SMALL-MOLECULE
RNA
BINDERS
123
INDUCTION
OF
MIRNAS
EXPRESSION:
TACKLING
THE
DECREASE
OF
TUMOR
SUPPRESSOR
MIRNAS
124
6.4.2
6.4.2.1
6.4.2.2
6.4.2.3
6.4.2.4
6.4.2.5
6.5
6.6
6.7
INHIBITION
OF
MIRNAS
PRODUCTION:
PRE
AND
PRI-MIRNA
BINDERS
125
DISCOVERY
OF
MIRNAS
INHIBITORS
BY
INTRACELLULAR
ASSAYS
125
TARGET-BASED
IN
VITRO
ASSAYS
127
DESIGN
OF
SPECIFIC
LIGANDS
OF
PRE
AND
PRI-MIRNAS
131
FRAGMENT-BASED
DRUG
DESIGN
138
DNA-ENCODED
LIBRARIES
(DELS)
139
INHIBITION
OF
RNA-PROTEIN
INTERACTIONS
IN
MIRNAS
PATHWAYS
140
ADDING
CLEAVAGE
PROPERTIES
TO
MIRNAS
INTERFERING
AGENTS
142
CONCLUSIONS
144
REFERENCES
144
7
PRE-MRNA
SPLICING
MODULATION
151
SCOTT
J.
BARRAZA
AND
MATTHEW
G.
WOLL
7.1
7.2
7.2.1
7.2.2
INTRODUCTION
151
OVERVIEW
OF
SPLICING
BIOLOGY
152
THE
SPLICEOSOME
152
CLASSES
OF
ALTERNATIVE
SPLICING
154
VIII
CONTENTS
7.3
7.3.1
7.3.1.1
7.3.1.2
7.3.1.3
7.3.1.4
7.3.1.5
7.3.1.6
PHARMACOLOGICAL
MECHANISMS
OF
SPLICING
MODULATION
155
CIS
AND
TRANS-REGULATORY
ELEMENTS
(SPLICING
FACTORS)
155
STABILIZATION
OF
CIS-REGULATORY
ELEMENTS
156
DESTABILIZATION
OF
CIS-REGULATORY
ELEMENTS
158
INHIBITION
OF
CIS-REGULATORY
RNA-PROTEIN
INTERACTIONS
158
INHIBITION
OF
TRANS-REGULATORY
ELEMENTS
160
DEGRADATION
OF
TRANS-REGULATORY
ELEMENTS
161
INHIBITION
OF
TRANS-REGULATORY
ELEMENT
PROTEIN-PROTEIN
INTERACTIONS
(PPIS)
162
7.3.1.7
STABILIZATION
OF
TRANS-REGULATORY
ELEMENT
RNA-PROTEIN
INTERACTIONS
(RPIS)
165
7.3.2
7.3.2.1
7.3.2.2
7.3.2.3
7.3.2.4
7.3.3
7.3.3.1
7.3.4
7.3.5
7.3.5.1
7.3.5.2
7.3.5.3
7.3.5.4
7.3.5.5
7.3.5.6
7.4
KINASES
AND
PHOSPHATASES
165
CHALLENGES
IN
TARGETING
KINASES
167
INHIBITION
OF
KINASES
168
ACTIVATION
AND
DEGRADATION
OF
KINASES
168
INHIBITION
AND
ACTIVATION
OF
PROTEIN
PHOSPHATASES
169
EPIGENETIC
WRITERS
AND
ERASERS
172
INHIBITION
OF
EPIGENETIC
WRITERS
172
RNA
HELICASES
174
DRUGGING
THE
SPLICEOSOME
175
INHIBITION
OFU2
SNRNP
RECOGNITION
OF
THE
3
'
-SPLICE
SITE
176
E7107
176
H3B-8800
177
STABILIZERS
OF
U1
SNRNP
RECOGNITION
OF
THE
5
'
-SPLICE
SITE
180
INTRODUCTION
TO
SPINAL
MUSCULAR
ATROPHY
(SMA)
180
RISDIPLAM
(EVRYSDI)
183
FUTURE
OUTLOOK
186
REFERENCES
188
8
PROSPECTS
FOR
RIBOSWITCHES
IN
DRUG
DEVELOPMENT
203
MICHAEL
G.
MOHSEN
AND
RONALD
R.
BREAKER
8.1
8.1.1
8.1.2
8.1.3
8.2
8.2.1
8.2.2
8.2.3
8.2.3.1
8.2.3.2
8.2.4
8.3
8.3.1
8.3.2
INTRODUCTION
203
THE
KNOWN
LANDSCAPE
OF
RIBOSWITCHES
203
RIBOSWITCHES
IN
DRUG
DEVELOPMENT
203
THE
NEED
FOR
NOVEL
ANTIBIOTICS
205
RIBOSWITCHES
AS
DRUG
TARGETS
207
WHY
TARGET
RIBOSWITCHES?
207
FEATURES
OF
A
DRUGGABLE
RIBOSWITCH
208
RIBOSWITCH-TARGETED
DRUGS
208
SMALL
MOLECULES
TARGETING
FMN
RIBOSWITCHES
208
OTHER
RIBOSWITCHES
TARGETED
IN
PROOF-OF-PRINCIPLE
DEMONSTRATIONS
209
BARRIERS
AND
FUTURE
DEVELOPMENTS
210
RIBOSWITCHES
AS
TOOLS
FOR
ANTIBIOTIC
DRUG
DEVELOPMENT
210
RIBOSWITCHES
AS
BIOSENSORS
210
A
RIBOSWITCH-BASED
FLUORIDE
SENSOR
ILLUMINATES
AGONISTS
OF
FLUORIDE
TOXICITY
211
CONTENTS
IX
8.3.3
A
RIBOSWITCH-BASED
ZTP
SENSOR
IDENTIFIES
INHIBITORS
OF
FOLATE
BIOSYNTHESIS
211
8.3.4
A
RIBOSWITCH-BASED
SAH
SENSOR
REVEALS
AN
INHIBITOR
OF
SAH
NUCLEOSIDASE
212
8.3.5
8.4
8.4.1
8.4.2
8.4.3
8.5
BARRIERS
AND
FUTURE
DEVELOPMENTS
213
APPLICATION
OF
RIBOSWITCHES
IN
GENE
THERAPY
213
CONSIDERATIONS
FOR
DESIGNER
RIBOSWITCHES
213
EUKARYOTIC
EXPRESSION
PLATFORMS
214
BARRIERS
AND
FUTURE
DEVELOPMENTS
216
CONCLUDING
REMARKS
217
ACKNOWLEDGMENT
218
REFERENCES
218
9
SMALL
MOLECULES
THAT
DEGRADE
RNA
227
NOAH
A.
SPRINGER,
SAMANTHA
M.
MEYER,
AMIRHOSSEIN
TOGHAVI,
JESSICA
L.
CHILDS-DISNEY,
AND
MATTHEW
D.
DISNEY
9.1
9.2
9.2.1
9.2.2
9.2.3
9.2.3.1
ANTISENSE
OLIGONUCLEOTIDE
DEGRADERS
227
SMALL-MOLECULE
DIRECT
DEGRADERS
228
N-HYDROXYPYRIDINE-2(1H)-THIONE
(N-HPT)
CONJUGATES
229
BLEOMYCIN
229
BLEOMYCIN
CONJUGATES
231
BLEOMYCIN
DEGRADERS
TARGETING
THE
R(CUG)
REPEAT
EXPANSION
THAT
CAUSES
DM1
231
9.2.3.2
BLEOMYCIN
DEGRADERS
TARGETING
R(CCUG)
REPEAT
EXPANSION
THAT
CAUSES
DM2
233
9.2.3.3
9.2.3.4
9.3
9.3.1
BLEOMYCIN
DEGRADERS
TARGETING
ONCOGENIC
PRECURSOR
MICRORNAS
233
CONCLUSIONS
AND
OUTLOOK
FOR
BLEOMYCIN-BASED
DIRECT
DEGRADERS
234
RIBONUCLEASE
TARGETING
CHIMERAS
(RIBOTACS)
235
RNASE
L
IS
AN
ENDOGENOUS
ENDORIBONUCLEASE
THAT
FUNCTIONS
AS
PART
OF
THE
INNATE
IMMUNE
RESPONSE
236
9.3.2
9.3.3
9.3.4
9.3.5
9.3.6
9.4
FIRST-GENERATION
RIBOTACS
TARGETING
ONCOGENIC
MIRNAS
236
SMALL-MOLECULE-BASED
RIBOTACS
239
COMPARISON
OF
BLEOMYCIN-BASED
DIRECT
DEGRADERS
AND
RIBOTACS
242
DISCOVERY
OF
ADDITIONAL
SMALL-MOLECULE
RNASE
L
ACTIVATORS
242
CONCLUSIONS
AND
OUTLOOK
FOR
RIBOTACS
243
SUMMARY
AND
OUTLOOK
FOR
SMALL-MOLECULE
RNA
DEGRADERS
244
REFERENCES
246
10
APPROACHES
TO
THE
IDENTIFICATION
OF
MOLECULES
ALTERING
PROGRAMMED
RIBOSOMAL
FRAMESHIFTING
IN
VIRUSES
253
ELINORE
A.
VANGRAAFEILAND,
DIEGO
M.
AREVALO,
AND
BENJAMIN
L.
MILLER
10.1
10.2
10.3
10.4
10.5
INTRODUCTION
253
MECHANISMS
OF
FRAMESHIFTING
256
TARGETING
FRAMESHIFTING
IN
HIV
257
TARGETING
FRAMESHIFTING
IN
SARS-COV-1
AND
SARS-COV-2
263
CONCLUSIONS
274
REFERENCES
274
CONTENTS
11
RNA-PROTEIN
INTERACTIONS:
A
NEW
APPROACH
FOR
DRUGGING
RNA
BIOLOGY
281
DALIA
M.
SOUEID
AND
AMANDA
L.
GARNER
11.1
11.1.1
11.1.2
11.1.3
11.1.4
11.1.5
11.2
11.2.1
11.2.2
MOLECULAR
BASIS
OF
RNA-PROTEIN
INTERACTIONS
282
RNA
RECOGNITION
MOTIFS
(RRMS)
282
DOUBLE-STRANDED
RNA-BINDING
DOMAINS
(DSRBD)
286
ZINC
FINGER
(ZNF)
DOMAINS
287
K
HOMOLOGY
(KH)
DOMAINS
289
OTHER
RBDS
290
REGULATION
AND
DYSREGULATION
OF
RNA-PROTEIN
INTERACTIONS
290
POOR
QUALITY
CONTROL
LEADS
TO
OVER
AND
UNDERPRODUCTION
OF
RBPS
292
RBPS
BECOME
OUT
OF
CONTROL,
MRNA
PROCESSING
GETS
A
MAKEOVER
(AND
HATES
IT)
294
11.2.3
11.2.4
11.2.5
RBP
SHUTTLING
OF
MRNA BECOMES
ASKEW
294
THE
RBP
IS
LOST
AND
WREAKS
HAVOC
ON
THE
CELL
295
RBPS
DICTATE
WHICH
MRNAS
ARE
TRANSLATED,
FAVORING
THEIR
TOXIC
FRIENDS
295
11.2.6
RBPS
AND
RNA
BECOME
VERY
CLIQUE-Y,
FORM
THEIR
OWN
COMPLEX
AND
CAUSE
STRESS
TO
THE
REST
OF
THE
CELL
296
11.3
EXPERIMENTAL
METHODS
TO
DETECT
AND
SCREEN
FOR
SMALL
MOLECULES
THAT
MODULATE
RNA-PROTEIN
INTERACTIONS
297
11.3.1
11.3.2
11.3.2.1
11.3.3
11.4
IN
VITRO
FLUORESCENCE-BASED
ASSAYS
297
IN
VITRO
CHEMILUMINESCENCE-BASED
ASSAYS
297
CELL-BASED
RPI
DETECTION
ASSAYS
300
CELL-BASED
RNA-PROTEIN
INTERACTION
SCREENING
301
CLOSING
REMARKS
302
REFERENCES
303
12
DRUGGING
THE
EPITRANSCRIPTOME
321
TANNER
W.
EGGERT
AND
RALPH
E.
KLEINER
12.1
12.2
INTRODUCTION
321
MODIFICATIONS
ON
MRNA:
N6-METHYLADENOSINE,
PSEUDOURIDINE,
AND
INOSINE
325
12.2.1
12.2.2
12.2.3
12.3
12.3.1
12.3.2
12.4
N6-METHYLADENOSINE
(M
6
A)
325
PSEUDOURIDINE
(V)
327
INOSINE
(I)
328
MODIFICATIONS
ON
TRNA
AND
RRNA
330
TRNA
MODIFICATIONS
330
RRNA
MODIFICATIONS
334
CONCLUDING
REMARKS
335
REFERENCES
336
CONTENTS
XI
INDEX
385
13
OUTLOOK
355
CHRISTOPHER
R.
FULLENKAMP,
XIAO
LIANG,
MARTIN
PETTERSSON,
AND
JOHN
SCHNEEKLOTH
JR.
13.1
13.2
INTRODUCTION
355
TARGET
SELECTION:
IDENTIFICATION
OF
THE
MOST
PROMISING
RNA
INTERVENTION
POINTS
357
13.3
DEVELOPMENT
OF
ROBUST
BIOPHYSICAL
METHODS,
ALTERNATIVE
STRATEGIES
FOR
TARGET
ENGAGEMENT,
AND
ACCURATE
AND
RELIABLE
FUNCTIONAL
MODELS
358
13.3.1
BIOPHYSICAL
METHODS
FOR
INTERROGATING
SMALL
MOLECULE-RNA
INTERACTIONS
358
13.3.2
13.3.3
CELLULAR
TARGET
ENGAGEMENT
METHODS
360
UNIQUE
CHALLENGES
FACED
IN
THE
DEVELOPMENT
OF
FUNCTIONAL
ASSAYS
FOR
STUDYING
SMALL
MOLECULE-RNA
INTERACTIONS
364
13.4
ACQUISITION
OF
HIGH-RESOLUTION
RNA
AND
RNA-LIGAND
STRUCTURES
IS
NEEDED
TO
ENABLE
THE
DEVELOPMENT
AND
VALIDATION
OF
COMPUTATIONAL
TOOLS
FOR
RNA-SMALL
MOLECULE
THERAPEUTIC
DISCOVERY
367
13.4.1
13.4.2
13.4.3
RNA
STRUCTURE
PREDICTION
367
COMPUTATIONAL
TOOLS
FOR
HIT
OPTIMIZATION
369
IMPLEMENTATION
OF
MOLECULAR
DYNAMICS
SIMULATIONS,
MACHINE
LEARNING,
AND
AI
TOOLS
TO
INTERROGATE
RNA-SMALL
MOLECULE
INTERACTIONS
371
13.5
DEPOSITION
OF
SMALL
MOLECULE-RNA
INTERACTION
DATA
WITH
RIGOROUS
EXPERIMENTAL
PROTOCOLS
AND
CONTROLS
IS
NEEDED
373
13.6
OUTLOOK:
THE
FUTURE
OF
SMALL
MOLECULE-BASED
RNA
THERAPEUTICS
IS
BRIGHT
375
REFERENCES
376 |
| any_adam_object | 1 |
| author2 | Schneekloth, John Pettersson, Martin |
| author2_role | edt edt |
| author2_variant | j s js m p mp |
| author_GND | (DE-588)1339302640 (DE-588)1339302675 |
| author_facet | Schneekloth, John Pettersson, Martin |
| building | Verbundindex |
| bvnumber | BV049840072 |
| ctrlnum | (OCoLC)1452586964 (DE-599)DNB1305295714 |
| edition | 1. Auflage |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000008c 4500</leader><controlfield tag="001">BV049840072</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240917</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">240828s2024 gw a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">23,N41</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1305295714</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527351008</subfield><subfield code="c">hardback : EUR 159.00 (DE) (freier Preis), circa EUR 142.90 (AT) (freier Preis)</subfield><subfield code="9">978-3-527-35100-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1452586964</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1305295714</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BW</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">540</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">RNA as a drug target</subfield><subfield code="b">the next frontier for medicinal chemistry</subfield><subfield code="c">edited by John Schneekloth and Martin Pettersson</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">[2024]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2024</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xvi, 392 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods and principles in medicinal chemistry</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Zielstruktur</subfield><subfield code="0">(DE-588)1028794711</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">RNS</subfield><subfield code="0">(DE-588)4076759-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biochemie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biomolecules (DNA, RNA, Peptides, etc.)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biomoleküle (DNA, RNA, Peptide)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biowissenschaften</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CH61: Wirkstoffforschung u. -entwicklung</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CHB1: Biomoleküle (DNA, RNA, Peptide)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Chemie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Chemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Drug Discovery & Development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LS36: Biochemie</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Life Sciences</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Wirkstoffforschung u. -entwicklung</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">RNS</subfield><subfield code="0">(DE-588)4076759-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Zielstruktur</subfield><subfield code="0">(DE-588)1028794711</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schneekloth, John</subfield><subfield code="0">(DE-588)1339302640</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pettersson, Martin</subfield><subfield code="0">(DE-588)1339302675</subfield><subfield code="4">edt</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Wiley-VCH</subfield><subfield code="0">(DE-588)16179388-5</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, ePDF</subfield><subfield code="z">978-3-527-84043-4</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, ePub</subfield><subfield code="z">978-3-527-84044-1</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, oBook</subfield><subfield code="z">978-3-527-84045-8</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="u">http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-35100-8/</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=035180035&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">vlb</subfield><subfield code="d">20231007</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#vlb</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-035180035</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV049840072 |
| illustrated | Illustrated |
| indexdate | 2024-10-15T10:04:54Z |
| institution | BVB |
| institution_GND | (DE-588)16179388-5 |
| isbn | 9783527351008 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-035180035 |
| oclc_num | 1452586964 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | xvi, 392 Seiten Illustrationen, Diagramme |
| publishDate | 2024 |
| publishDateSearch | 2024 |
| publishDateSort | 2024 |
| publisher | Wiley-VCH |
| record_format | marc |
| series2 | Methods and principles in medicinal chemistry |
| spelling | RNA as a drug target the next frontier for medicinal chemistry edited by John Schneekloth and Martin Pettersson Weinheim Wiley-VCH [2024] © 2024 xvi, 392 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Methods and principles in medicinal chemistry Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Zielstruktur (DE-588)1028794711 gnd rswk-swf RNS (DE-588)4076759-0 gnd rswk-swf Biochemie Biochemistry Biomolecules (DNA, RNA, Peptides, etc.) Biomoleküle (DNA, RNA, Peptide) Biowissenschaften CH61: Wirkstoffforschung u. -entwicklung CHB1: Biomoleküle (DNA, RNA, Peptide) Chemie Chemistry Drug Discovery & Development LS36: Biochemie Life Sciences Wirkstoffforschung u. -entwicklung (DE-588)4143413-4 Aufsatzsammlung gnd-content RNS (DE-588)4076759-0 s Zielstruktur (DE-588)1028794711 s Arzneimittelentwicklung (DE-588)4143176-5 s DE-604 Schneekloth, John (DE-588)1339302640 edt Pettersson, Martin (DE-588)1339302675 edt Wiley-VCH (DE-588)16179388-5 pbl Erscheint auch als Online-Ausgabe, ePDF 978-3-527-84043-4 Erscheint auch als Online-Ausgabe, ePub 978-3-527-84044-1 Erscheint auch als Online-Ausgabe, oBook 978-3-527-84045-8 X:MVB http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-35100-8/ DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=035180035&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p vlb 20231007 DE-101 https://d-nb.info/provenance/plan#vlb |
| spellingShingle | RNA as a drug target the next frontier for medicinal chemistry Arzneimittelentwicklung (DE-588)4143176-5 gnd Zielstruktur (DE-588)1028794711 gnd RNS (DE-588)4076759-0 gnd |
| subject_GND | (DE-588)4143176-5 (DE-588)1028794711 (DE-588)4076759-0 (DE-588)4143413-4 |
| title | RNA as a drug target the next frontier for medicinal chemistry |
| title_auth | RNA as a drug target the next frontier for medicinal chemistry |
| title_exact_search | RNA as a drug target the next frontier for medicinal chemistry |
| title_full | RNA as a drug target the next frontier for medicinal chemistry edited by John Schneekloth and Martin Pettersson |
| title_fullStr | RNA as a drug target the next frontier for medicinal chemistry edited by John Schneekloth and Martin Pettersson |
| title_full_unstemmed | RNA as a drug target the next frontier for medicinal chemistry edited by John Schneekloth and Martin Pettersson |
| title_short | RNA as a drug target |
| title_sort | rna as a drug target the next frontier for medicinal chemistry |
| title_sub | the next frontier for medicinal chemistry |
| topic | Arzneimittelentwicklung (DE-588)4143176-5 gnd Zielstruktur (DE-588)1028794711 gnd RNS (DE-588)4076759-0 gnd |
| topic_facet | Arzneimittelentwicklung Zielstruktur RNS Aufsatzsammlung |
| url | http://www.wiley-vch.de/publish/dt/books/ISBN978-3-527-35100-8/ http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=035180035&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT schneeklothjohn rnaasadrugtargetthenextfrontierformedicinalchemistry AT petterssonmartin rnaasadrugtargetthenextfrontierformedicinalchemistry AT wileyvch rnaasadrugtargetthenextfrontierformedicinalchemistry |